Cargando…

The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine

Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 12, is expressed in sites of injury, chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Julier, Ziad, Martino, Mikaël M., de Titta, Alexandre, Jeanbart, Laura, Hubbell, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338432/
https://www.ncbi.nlm.nih.gov/pubmed/25708982
http://dx.doi.org/10.1038/srep08569
_version_ 1782481213213114368
author Julier, Ziad
Martino, Mikaël M.
de Titta, Alexandre
Jeanbart, Laura
Hubbell, Jeffrey A.
author_facet Julier, Ziad
Martino, Mikaël M.
de Titta, Alexandre
Jeanbart, Laura
Hubbell, Jeffrey A.
author_sort Julier, Ziad
collection PubMed
description Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 12, is expressed in sites of injury, chronic inflammation, and solid tumors. Although its function is not well understood, FNIII EDA is known to agonize Toll-like receptor 4 (TLR4). Here, by producing various FN fragments containing FNIII EDA, we found that FNIII EDA's immunological activity depends upon its local intramolecular context within the FN chain. N-terminal extension of the isolated FNIII EDA with its neighboring FNIII repeats (FNIII 9-10-11) enhanced its activity in agonizing TLR4, while C-terminal extension with the native FNIII 12-13-14 heparin-binding domain abrogated it. In addition, we reveal that an elastase 2 cleavage site is present between FNIII EDA and FNIII 12. Activity of the C-terminally extended FNIII EDA could be restored after cleavage of the FNIII 12-13-14 domain by elastase 2. FN being naturally bound to the ECM, we immobilized FNIII EDA-containing FN fragments within a fibrin matrix model along with antigenic peptides. Such matrices were shown to stimulate cytotoxic CD8(+) T cell responses in two murine cancer models.
format Online
Article
Text
id pubmed-4338432
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43384322015-03-04 The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine Julier, Ziad Martino, Mikaël M. de Titta, Alexandre Jeanbart, Laura Hubbell, Jeffrey A. Sci Rep Article Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 12, is expressed in sites of injury, chronic inflammation, and solid tumors. Although its function is not well understood, FNIII EDA is known to agonize Toll-like receptor 4 (TLR4). Here, by producing various FN fragments containing FNIII EDA, we found that FNIII EDA's immunological activity depends upon its local intramolecular context within the FN chain. N-terminal extension of the isolated FNIII EDA with its neighboring FNIII repeats (FNIII 9-10-11) enhanced its activity in agonizing TLR4, while C-terminal extension with the native FNIII 12-13-14 heparin-binding domain abrogated it. In addition, we reveal that an elastase 2 cleavage site is present between FNIII EDA and FNIII 12. Activity of the C-terminally extended FNIII EDA could be restored after cleavage of the FNIII 12-13-14 domain by elastase 2. FN being naturally bound to the ECM, we immobilized FNIII EDA-containing FN fragments within a fibrin matrix model along with antigenic peptides. Such matrices were shown to stimulate cytotoxic CD8(+) T cell responses in two murine cancer models. Nature Publishing Group 2015-02-24 /pmc/articles/PMC4338432/ /pubmed/25708982 http://dx.doi.org/10.1038/srep08569 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Julier, Ziad
Martino, Mikaël M.
de Titta, Alexandre
Jeanbart, Laura
Hubbell, Jeffrey A.
The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
title The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
title_full The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
title_fullStr The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
title_full_unstemmed The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
title_short The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
title_sort tlr4 agonist fibronectin extra domain a is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338432/
https://www.ncbi.nlm.nih.gov/pubmed/25708982
http://dx.doi.org/10.1038/srep08569
work_keys_str_mv AT julierziad thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT martinomikaelm thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT detittaalexandre thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT jeanbartlaura thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT hubbelljeffreya thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT julierziad tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT martinomikaelm tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT detittaalexandre tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT jeanbartlaura tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine
AT hubbelljeffreya tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine